Clinical Trials Browser

Phase 1/2 × Ovarian Neoplasms × Fenretinide × Clear all

NCT01535157 2020-08-27

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Phase 1/2 Terminated

Ovarian Neoplasms